Westbrook Recovery

Suboxone vs Methadone: How to Choose for Opioid Addiction

Last updated

Both are established medications for opioid use disorder with strong evidence behind them. Suboxone (buprenorphine with naloxone) is a partial opioid agonist that can be prescribed in an ordinary medical office and picked up at a pharmacy. Methadone is a full agonist dispensed through federally regulated opioid treatment programs, which usually means daily in-person visits at the start. For most people the deciding factor is not which drug is stronger but which one they can realistically access and keep taking.

The short version

  1. Where you get it: Pharmacy vs Certified programme — the difference that decides most real cases
  2. Facilities offering it: 59.2% vs 13.7% — our count of the federal directory
  3. Typical early dosing: Periodic appointments vs Often daily, observed — take-home doses are earned over time on methadone
  4. Receptor action: Partial agonist vs Full agonist — the ceiling effect is why buprenorphine is less restricted

Side by side

  • Drug class

    Suboxone
    Partial opioid agonist
    Methadone
    Full opioid agonist

  • Where you get it

    Suboxone
    Office-based prescriber, pharmacy pickup
    Methadone
    Licensed opioid treatment program

  • Early-stage visits

    Suboxone
    Periodic appointments
    Methadone
    Often daily, observed dosing

  • Take-home doses

    Suboxone
    Standard prescription
    Methadone
    Earned over time under federal rules

  • Overdose ceiling

    Suboxone
    Yes — effect plateaus at higher doses
    Methadone
    No ceiling effect

  • Best suited to

    Suboxone
    Moderate dependence, stable housing and transport
    Methadone
    Long-term or high-dose use, when buprenorphine has not held

  • Withdrawal on starting

    Suboxone
    Must be in withdrawal first to avoid precipitated withdrawal
    Methadone
    No such requirement

  • Rural availability

    Suboxone
    Wider — any qualified prescriber
    Methadone
    Limited by program locations
Three figures from the Cochrane review of buprenorphine maintenance: 31 trials, risk ratio 1.82 against placebo at high dose
Retention is the outcome the others depend on: a medication nobody is still taking at six months delivers none of its benefits.
Table comparing methadone and buprenorphine on retention, suppression of use, availability, pharmacy collection
The medication with the better retention evidence is the harder one to reach. That is the actual shape of this decision.

In numbers

  • Where you get it

    PharmacyvsCertified programme

    the difference that decides most real cases

  • Facilities offering it

    59.2%vs13.7%

    our count of the federal directory

  • Typical early dosing

    Periodic appointmentsvsOften daily, observed

    take-home doses are earned over time on methadone

  • Receptor action

    Partial agonistvsFull agonist

    the ceiling effect is why buprenorphine is less restricted

Suboxone makes sense when

  • Daily travel to a clinic is not realistic for your work or family situation
  • You live far from the nearest opioid treatment program
  • You want a medication filled at a regular pharmacy
  • Your prescriber judges partial agonist treatment appropriate for your history

Methadone makes sense when

  • Buprenorphine has not adequately controlled cravings or withdrawal for you
  • Your opioid use has been long-term and at high doses
  • The daily structure of a program is a support rather than a barrier
  • A program is accessible from where you live
Bar chart comparing visits required at the start: Suboxone through periodic appointments, methadone often daily and observed
For most people the deciding factor is not pharmacology but whether daily attendance is realistic.
Table matching circumstances to Suboxone or methadone: distance to a certified programme, work commitments, previous attempts
Both are supported by strong evidence. This is a clinical decision made with a prescriber, and access usually shapes it more than anything else.
Table of all forms of buprenorphine and methadone: daily film, with naloxone, monthly injection, implant, observed liquid
Buprenorphine comes in more forms than most comparisons mention, and that is often what decides which is workable.

Access is not symmetrical, and the gap is four to one

Our analysis

Both medications are proven. But methadone must be dispensed through a federally regulated programme, and that regulatory difference shows up directly in how many places can give it to you.

59.2%
offer buprenorphine
6,058 facilities
13.7%
offer methadone
1,405 facilities: four times fewer
12.8%
are certified opioid treatment programmes
the only settings that dispense methadone

How we got this: we pulled the full public listing from SAMHSA’s FindTreatment.gov on , removed duplicate entries by name, street and ZIP, and counted how many of the 10,233 remaining facilities report each service. SAMHSA publishes the directory; it does not publish these proportions — see how the count is made. Repeat the pull and you will get the same numbers, give or take facilities that opened or closed since.

What these numbers cannot tell you: they are self-reported by facilities, they describe availability rather than quality, and a national proportion says nothing about what is open near you this week. Use them to know what to ask for, not to decide where to go.

What Suboxone actually is

Suboxone is a brand name for a combination of buprenorphine and naloxone. Buprenorphine is the active component: a partial opioid agonist, meaning it occupies the same receptors as heroin or oxycodone but activates them only partially and has a ceiling on that effect. In practice that is what makes it usable outside a clinic: it relieves withdrawal and craving without producing the escalating effect that a full agonist does, and the ceiling reduces overdose risk relative to full agonists. The naloxone component is not doing anything useful when the film or tablet is taken as directed; it is there to discourage injection, because injected naloxone precipitates withdrawal. Buprenorphine is available at 59.2% of the facilities in the federal directory, and it can be prescribed and collected from a pharmacy like other prescriptions.

Why it comes in different forms

You will see buprenorphine on its own as well as in combination with naloxone, and in film, tablet and long-acting injectable forms. The single-agent version is used in specific circumstances, pregnancy among them. Which formulation is appropriate is a prescribing decision, not a preference to arrive with.

What methadone actually is

Methadone is a full opioid agonist: it activates the same receptors completely, with no ceiling effect. That is the source of both its strength and its restrictions. It is long-acting and, at an adequate dose, holds withdrawal and craving steady across a full day, which is why it remains effective for people with high tolerance and for those whom buprenorphine has not held. Because it is a full agonist, the risk profile during induction is different and the dose has to be raised carefully over days rather than found immediately. In the US, methadone for opioid use disorder can only be dispensed through a federally certified opioid treatment programme; the same drug prescribed for pain is not subject to that rule. Only 13.7% of facilities in the directory offer it, and 12.8% are certified programmes.

What daily dosing looks like in practice

Early in treatment, dosing is observed at the programme — you attend, take the dose in front of staff, and leave. Take-home doses are earned over time against criteria that include stability and the length of time in the programme. For someone with a fixed work schedule or without transport, that daily attendance is frequently the deciding constraint, which is why the practical question is often not which medication is better but which one you can actually get to.

The differences that actually matter

Set aside the pharmacology for a moment: the differences that change real decisions are narrower than the comparisons suggest. Where you collect it: a pharmacy against a certified programme — determines whether treatment fits around a job. Who can prescribe it determines how long you wait to start. What happens if a dose is missed differs, because a full agonist and a partial agonist behave differently. And what the first week involves differs sharply: buprenorphine requires you to be in early withdrawal before the first dose, while methadone starts from a low dose and is raised gradually. Both are supported by strong evidence for reducing illicit opioid use and overdose death. Neither is a lesser option, and the choice is made with a prescriber who knows the history.

What both have in common

Both are medications for a chronic condition rather than a course to be completed, both work better alongside counselling than either does alone, and both are compatible with mutual-aid attendance, though individual groups vary in how they treat members on medication. Stopping either abruptly returns withdrawal and craving, and the period after stopping carries raised overdose risk because tolerance has fallen.

What the evidence says about which one works better

Most comparisons stop at “both are effective”, which is true and unhelpful. The Cochrane review of buprenorphine maintenance (Mattick and colleagues, 31 trials, 5,430 participants) went further and compared the two head to head. Its conclusion is more pointed than the usual summary: methadone is superior to buprenorphine in retaining people in treatment, and methadone equally suppresses illicit opioid use. That finding deserves to be stated plainly, and then placed next to the fact that only 13.7% of US facilities offer methadone at all.

The retention finding, precisely

Against placebo, buprenorphine performed well: high-quality evidence that it retained people in treatment at every dose examined, with risk ratios of 1.50 at low doses, 1.74 at medium and 1.82 at high doses. Suppression of illicit opioid use, though, reached significance only at doses of 16 mg or more. Compared with methadone directly, the picture changes: buprenorphine retained fewer people when doses were delivered flexibly and at low fixed doses. Where medium or high fixed doses were used, the two appeared no different on both retention and suppression.

Why the fixed-dose result does not rescue the comparison

It is tempting to read “no different at fixed medium or high doses” as a tie, and the review closes that door itself: fixed doses are rarely used in clinical practice, so the flexible-dose results are the ones relevant to patient care. In other words, the condition under which the two look equivalent is not the condition most people are treated under. Retention matters because it is the outcome everything else depends on — a medication nobody is still taking at six months is not producing any of its benefits.

The tension nobody names

Put the two facts together and the awkward shape becomes visible. The medication with the better retention evidence is the one available at 13.7% of facilities and requiring daily attendance at a certified programme. The medication that is easier to reach, prescribe and continue is the one that retains slightly fewer people. That is a real trade-off rather than a marketing point for either side, and it explains why the sensible question is still the practical one: which of these can you actually start and keep going with, given where you live and how your week is arranged.

What this does not mean

It does not mean buprenorphine is a weak option — the same review found it clearly effective against placebo on high-quality evidence, and for many people it is the difference between treatment and none. It does not mean someone doing well on buprenorphine should switch. And it says nothing about side-effect profiles or about individual response, both of which vary. The finding is a population-level average, and a prescriber is treating a person.

Extended-release buprenorphine: the monthly injection

Buprenorphine is not only a daily film. Extended-release injectable forms exist — Sublocade and Brixadi are the US brands — and in our count of the federal directory 33.7% of facilities report offering an extended-release buprenorphine injection, with a further 10.4% offering an implant. For anyone whose objection to buprenorphine is the daily dose rather than the drug, that changes the comparison considerably.

How the injection works

Sublocade is given subcutaneously, not into muscle, and the labelled regimen is two initial doses of 300 mg followed by 100 mg monthly for maintenance, with 300 mg monthly considered where the benefits outweigh the risks. Injection sites are rotated between doses. The label is explicit that it should be used as part of a complete treatment programme including counselling and psychosocial support — it is not a standalone substitute for the rest of treatment.

You start on the film first

This surprises people who hope to skip the daily medication entirely. The indication is for patients who have initiated treatment with a transmucosal buprenorphine product or who are already being treated with buprenorphine. The reason is practical: the film establishes that you tolerate buprenorphine before a month’s worth is placed under the skin where it cannot be removed.

The boxed warning, and why it is only available through a restricted programme

Sublocade carries a boxed warning: serious harm or death could result if it is administered intravenously, because the formulation forms a solid mass on contact with body fluids. For that reason it is available only through a restricted REMS programme, and the healthcare settings and pharmacies that order and dispense it must be certified. In practice that means it is administered by a provider in a certified setting rather than collected and injected at home.

Fentanyl and how the induction is done

The label reports a finding worth knowing given what is in the drug supply now. Comparing rapid induction — a single dose of transmucosal buprenorphine before the injection — with standard induction of at least seven days on the film, three fentanyl-positive patients in the rapid arm had serious adverse events associated with opioid withdrawal, and none did in the standard arm. Where fentanyl is involved, the slower route is the one with the safety record behind it.

How methadone programmes actually work now

A great deal of what is written about methadone clinics describes rules that no longer apply. In February 2024 SAMHSA finalised the first substantial update to the federal regulations governing opioid treatment programmes in over twenty years — 42 CFR Part 8 — effective 2 April 2024 with a compliance date of 2 October 2024. If you read something describing a rigid points-based schedule for take-home doses, check its date.

What changed in 2024

The flexibilities introduced during the COVID-19 public health emergency were made permanent rather than allowed to lapse. Practitioners are no longer required to follow rigid criteria to determine how many take-home doses a patient may receive; the rule directs them instead towards overdose prevention, shared decision-making with the patient, and the person’s own circumstances. The rule also removed stigmatising language from the regulations and widened who may order admission.

Take-home doses are no longer a formula

Under the old regime the number of take-home doses tracked a schedule based largely on time in treatment. Now it is a clinical judgement made with you. That is a genuine improvement and it also means the answer varies by programme: two clinics operating under identical federal rules can take different views. It is therefore a fair and specific question to ask before enrolling — how does this programme approach take-homes, and what does it look like in the first month.

Telehealth

The rule permanently allows initiation of buprenorphine via telehealth, including audio-only under defined conditions, and permits audio-visual telehealth in the methadone initiation process in specified circumstances. For someone at distance from a programme, that is the provision most likely to change what is realistically available — though ongoing methadone dosing still happens in person at a certified programme.

Are methadone programmes free?

Rarely free outright, and less expensive than people assume. Programmes typically charge a weekly or monthly fee covering dosing and the counselling required by certification. Public funding does most of the work here: in our count 83.4% of facilities accept Medicaid and 54.5% take state funding outside Medicaid, and opioid treatment programmes are among the services states fund most consistently. Ask the programme directly what it bills, and ask the state authority what it funds — the two answers together usually settle the question.

Why methadone access is regulated differently

Methadone for opioid use disorder is dispensed through certified opioid treatment programs under federal regulation, which is why it involves programme enrolment and, initially, observed daily dosing. Buprenorphine products such as Suboxone can be prescribed in general medical settings. This regulatory difference, not effectiveness — is the single biggest practical divide between the two, and it is why availability varies so sharply between urban and rural areas.

What gets tested, what gets recorded, and who can see it

This is the cluster of questions people search most and ask least, because asking feels like admitting something. The answers are more reassuring than the silence around them suggests, and they changed recently.

Your treatment records are protected more tightly than ordinary medical records

Substance use disorder records held by a federally assisted programme fall under 42 CFR Part 2, a confidentiality rule stricter than HIPAA: disclosure generally requires your written consent even where other health information could be shared. That framework was updated by a final rule issued in February 2024, effective that April, which aligns Part 2 more closely with HIPAA under the CARES Act; the two-year implementation period ended and enforcement of the updated rules began on 16 February 2026. The practical exceptions remain narrow — medical emergencies, court orders, and disclosures you have agreed to, such as reporting to a probation officer.

Prescription monitoring databases

Buprenorphine is a prescription controlled substance, so like any other it is recorded in your state prescription drug monitoring programme and visible to prescribers and pharmacists who check it. Methadone dispensed for opioid use disorder at a certified programme sits differently, and whether it appears in the state database varies by state — some require programmes to report, others exempt them. If this matters to you, it is a direct question worth asking the programme rather than assuming either way.

What programmes test for

Testing is routine in methadone programmes and common in buprenorphine treatment, and panels vary. Standard panels look for opioids, cocaine, amphetamines, benzodiazepines and cannabis; many programmes add a specific test for buprenorphine or methadone to confirm you are taking what is prescribed, since neither shows on a standard opiate screen. Substances such as kratom and gabapentin are not on most standard panels and require a specific test. Ask which panel a programme runs, because the answer determines what a result means, and a positive result is clinical information used to adjust the plan, not automatically grounds for discharge.

What the monthly injection is actually like

Since extended-release buprenorphine is now offered by a third of the directory, the practical questions about it deserve a straight answer rather than a brochure.

The lump is expected

The label instructs the provider to tell you that you may have a lump for several weeks which will decrease in size over time, and to avoid rubbing or massaging the site or letting belts, waistbands or sleeves press on it. That is the depot itself, doing what it is designed to do — releasing over the month. Knowing it is expected prevents a fair amount of alarm at week two.

Common effects, and the one that needs reporting

Reactions reported in at least 5% of people were constipation, headache, nausea, itching at the injection site, vomiting, raised liver enzymes, fatigue and pain at the injection site. Separately, the label warns of a risk of serious injection site reactions, and notes the likelihood increases with inadvertent intramuscular or intradermal administration. So ordinary tenderness and a firm lump are expected; a site that is spreading, hot, or worsening rather than settling is one to have looked at rather than to wait out.

Sites and rotation

The abdomen is the usual site, with the back of the upper arm, buttock and thigh also used, and sites are rotated between doses. The provider is instructed to avoid areas that are irritated, reddened, bruised, infected or scarred, and to check the site at each visit for signs of infection or of attempts to remove the depot. That last check exists because the depot cannot be taken back once placed, which is the trade-off for not having to remember anything for a month.

Precipitated withdrawal: the thing to understand before your first dose

Because buprenorphine binds strongly to opioid receptors while only partially activating them, starting it too soon after a full agonist can displace that drug and trigger sudden, severe withdrawal. This is why prescribers instruct patients to be in mild-to-moderate withdrawal before the first dose. Methadone does not carry this requirement. Anyone starting buprenorphine should follow the induction timing their prescriber gives rather than improvising it.

How long people stay on medication

Both are intended for as long as they are helping: this is maintenance treatment, not a taper with a fixed finish line. Stopping early is associated with return to use and, because tolerance falls, with elevated overdose risk. Decisions about tapering belong with the prescriber and are usually made after a sustained period of stability, not on a preset schedule.

Two situations that change the calculation

Both come up often enough in the outpatient setting that they belong in the decision rather than after it.

When there is also a mental health condition

Co-occurring depression, anxiety or PTSD is the norm rather than the exception — 69.5% of facilities in the federal directory report treating co-occurring conditions. Neither medication treats those directly, and neither is a contraindication to psychiatric medication, but interactions matter and prescribing is easier to coordinate when one team handles both. If the choice is between a clinic that offers integrated care and one that does not, that usually matters more than which of the two medications you start on.

Court-involved and probation situations

Some drug courts, probation conditions and treatment programmes have historically restricted agonist medication, requiring abstinence-based treatment instead: a position at odds with the clinical evidence and increasingly challenged on legal grounds. If you are under court supervision, confirm in writing what is permitted before starting, and involve the prescribing clinician in that conversation. A documented clinical recommendation carries weight that a patient request does not.

What about naltrexone

Extended-release naltrexone is a third option and works differently: it is an opioid antagonist, blocking effects rather than partially activating receptors. It requires full detoxification before starting, which is a meaningful barrier for many people. It is worth discussing as an alternative, particularly where agonist treatment is not wanted or available.

The questions people actually ask about these two

These come up more often in searches than any comparison of the two medicines does, and the answers are mostly not what people expect. Everything below is a summary of what federal agencies and published clinical sources say, with links in the sources list. It is not a prescribing opinion, and none of it replaces the conversation with whoever would be treating you.

Is Suboxone addictive?

The honest answer separates two things that ordinary language runs together. Physical dependence means the body has adapted, so stopping abruptly produces withdrawal — buprenorphine does cause that, as do many medicines that nobody calls addictive. Addiction, in the clinical sense, means compulsive use despite harm, loss of control, and life falling apart around the use. NIDA’s position is that when taken as prescribed for opioid use disorder, buprenorphine and methadone prevent craving and withdrawal without producing the intense high that other opioids do, which is what makes them less addictive rather than a swap. The agency addresses the substitution question directly: because both have a gradual onset and produce stable drug levels in the brain, people maintained on them do not experience a rush. Withdrawal on stopping is real but milder than from other opioids, and it is managed by reducing the dose gradually rather than stopping abruptly.

Is Suboxone a narcotic, or an opioid?

Buprenorphine is an opioid: a partial agonist at the same receptors, and it is a controlled substance in Schedule III. So in the legal sense of the word, yes. What the label does not tell you is the part that matters clinically: the ceiling effect. Increasing the dose of a partial agonist stops producing a proportionally increasing effect beyond a point, which is why its overdose risk profile differs from a full agonist and why it can be prescribed and dispensed through ordinary pharmacies. Methadone is also an opioid, a full agonist, and is Schedule II. Both being opioids is the reason they work; it is not evidence against using them.

How does it feel, and how long before it works?

Descriptions from clinical sources are consistent and fairly undramatic: at an adequate dose, withdrawal symptoms settle and craving quietens, and people report feeling normal rather than high. That flatness is the intended effect. Sublingual buprenorphine is absorbed over roughly fifteen to thirty minutes as the film or tablet dissolves, with effects felt within about an hour of a first dose, though the dose that actually holds someone steady is usually found over several days. Methadone is slower and longer-acting, and finding the right dose deliberately takes days to weeks, which is a safety feature of how a full agonist has to be started, not a delay in the system.

Is methadone addictive, and does it make you sleepy?

The same distinction applies: methadone produces physical dependence, and at a dose suited to the person it is not intended to produce sedation or a high. Persistent drowsiness generally indicates the dose or the combination with other medicines needs review rather than being an inevitable feature of treatment, that is a conversation with the programme, and it is one they expect to have. Sedation is more likely when methadone is combined with benzodiazepines, alcohol or other sedatives, which is why programmes ask repeatedly about everything else you are taking.

How do methadone clinics actually work?

A certified opioid treatment programme is the only setting in the US where methadone can be dispensed for opioid use disorder. In practice that means attending the programme, taking the dose under observation, and leaving — daily at first. Take-home doses are earned over time against criteria that include stability in treatment and time enrolled. Programmes also provide counselling and monitoring as part of the certification. Only 12.8% of the facilities in the federal directory are certified programmes, which is why distance to the nearest one is so often the deciding factor rather than any judgement about the medicine.

Does either one damage your teeth?

This question is usually asked about methadone, and the documented warning is actually about buprenorphine. In January 2022 the FDA warned that dental problems — tooth decay, cavities, oral infections and tooth loss — have been reported with buprenorphine medicines dissolved in the mouth, including Suboxone. The FDA identified 305 cases, 131 of them serious, some in people with no history of dental trouble. The agency was equally clear that the benefits of the medicine outweigh this risk and that people should not stop taking it on their own. The mitigation is straightforward: after the film or tablet has fully dissolved, take a large sip of water, swish it gently around the teeth and gums, swallow, and wait at least an hour before brushing. Patches and injections have not been associated with the same problem. Methadone is associated with dry mouth, which carries its own dental risk through a different mechanism — worth mentioning to a dentist either way.

Will these show up on a drug test?

Usually not on the test people are worried about. A standard opiate immunoassay: the common workplace screen — is designed around morphine-like compounds and generally does not detect buprenorphine or methadone; both require a specific assay to be found. Detection windows vary with the individual, the dose, how long they have been taking it and which test is used, so any single number you read is at best an average. If a test is being done for a job, a court or a programme, the useful step is telling whoever is ordering it that you are in treatment, and asking which panel they run.

What about cannabis, or other substances, while on medication?

Cannabis use is not a medical contraindication to buprenorphine or methadone, and evidence has not shown that it prevents treatment from working. Programmes nonetheless differ in policy, and some make continued use a condition of take-home privileges: this is a programme rule rather than a pharmacological one, and it is fair to ask what the policy is before enrolling. The combinations that genuinely raise risk are sedatives: benzodiazepines, alcohol and other central nervous system depressants taken alongside either medication increase the risk of dangerous respiratory depression. That is the interaction worth being candid with a prescriber about, even where the honesty is uncomfortable.

What does it cost without insurance?

There is no single figure, and anyone quoting one is generalising. Buprenorphine is available as a generic, which puts it within reach through discount pharmacy pricing in a way the brand is not; methadone programmes typically charge a weekly or monthly fee that covers dosing and the required counselling. What is worth knowing is that the routes below the sticker price are wider than most people assume: 83.4% of facilities in our count accept Medicaid, 54.5% take state funding outside Medicaid, and 40.0% operate a sliding fee scale. Asking for the sliding scale by name is the step people most often skip.

Five-step diagram of starting monthly buprenorphine injection: begin on film, at least seven days, two 300 mg doses
The label requires starting on the film first, and the slower induction is the one with the safety record where fentanyl is involved.
Five-step diagram of starting medication: assessment, induction, stabilisation, maintenance, and take-home privileges
Descriptive only. Induction timing in particular is a clinical decision — starting buprenorphine too early causes precipitated withdrawal.
Five-step diagram of the 2024 federal rule for opioid treatment programmes: first update in over twenty years
Anything describing a rigid points schedule for take-home doses was written before this rule and is now out of date.
Checklist of six questions to ask a methadone programme: take-home approach, dosing hours, missed doses, cost and billing
Since take-homes became a clinical judgement, two programmes under identical federal rules can give you very different answers.

Where this sits in the system of care

Addiction treatment is organised into levels of care, and clinicians choose between them using the ASAM criteria (six dimensions covering withdrawal risk, medical and psychiatric conditions, readiness, relapse risk and, decisively, the environment you return to. Facilities are licensed by the state and many hold additional accreditation from bodies such as the Joint Commission or CARF; that status is worth confirming for any specific programme. Percentages below are our count of how many facilities in the federal directory report offering each level of care.

  1. Detox19.5% of facilitiesmedical withdrawal management, 3–7 daysDetox vs rehab
  2. Residential21.4% of facilitieslive on site, 24-hour staffingInpatient vs outpatient
  3. PHP20–30 structured hours a week, sleep at homePHP vs IOP
  4. IOP9–19 hours a week, usually compatible with workPHP vs IOP
  5. Standard outpatient85.4% of facilities1–8 hours a week, the maintenance levelMutual aid options
“Remaining in treatment for an adequate period of time is critical.”

Programmes for specific groups

Facilities also report dedicated programming, and the coverage is wider than most people expect, worth asking about before assuming a programme will not fit. From our count: 42.7% run programmes for adolescents, 39.2% for veterans, 38% for pregnant and postpartum women, and 25% provide services in Spanish. Medication for opioid use disorder is available at 59.2% (buprenorphine) and 13.7% (methadone).

Cost and coverage vary by level: residential care is the tier insurers scrutinise most and almost always requires prior authorisation before admission. See what your plan covers and how to pay without insurance. Family involvement is a standard part of most programmes, and aftercare planning ( step-down to a lower level, sober living, relapse prevention) should be discussed before admission, not at discharge. If a mental health condition is also present, ask specifically whether the programme is staffed for co-occurring disorders: 69.5% of facilities in the directory report treating them, but that is a self-reported field worth confirming.

Five-step diagram of what happens when doses are missed on buprenorphine or methadone
The period around interrupted treatment is the higher-risk window for both, and restarting at the old dose is the move to avoid.
Bar chart of medication availability across US facilities: buprenorphine 59.2%, prescribing 54.0%
The four-to-one gap is regulatory, not clinical. The injectable form, widely assumed to be rare, is offered by a third of the directory.
Bar chart of medication for opioid use disorder availability: buprenorphine at 59.2% of facilities, methadone at 13.7%, certified opioid treatment programmes at 12.8%
The four-to-one gap between buprenorphine and methadone availability is a regulatory fact, not a clinical judgement about which works better.
Bar chart of how many US treatment facilities offer each level of care: outpatient 85.4%, residential 21.4%, medical detox 19.5%, hospital inpatient 5.9%
Outpatient care is nearly universal; residential and detox are the scarce tiers. That scarcity is part of why they cost what they do and why waits exist.
Bar chart of payment types accepted by US addiction treatment facilities: cash 91.6%, private insurance 80.7%, Medicaid 83.4%, Medicare 55.2%, state-financed 54.5%, military 49.6%, sliding scale 40.0%, payment assistance 22.5%
Accepting your insurer is not the same as your plan covering the level of care you need. The two questions have to be asked separately.
Bar chart comparing Medicaid acceptance among treatment facilities in the nine largest US states
Where the share is low, the reason is usually how the state runs its programme rather than reluctance among facilities.
Checklist of the six ASAM assessment dimensions: withdrawal risk, medical conditions, emotional and behavioural conditions, readiness to change, relapse potential, and recovery environment
This is the framework US programmes and insurers actually use. The sixth dimension — what home is like — is the one families most often underestimate.
Checklist of six questions to ask a treatment facility about network status, prior authorisation, all-in cost, medication availability, aftercare and accreditation
How plainly a programme answers these is itself information about how it operates.
Three figures: 69.5% of facilities treat co-occurring disorders, 59.8% offer trauma-informed care, 19.5% run medical detox
Co-occurring capability is self-reported. Ask what it means concretely, which clinicians are on staff, and whether psychiatric medication can be prescribed and reviewed on site.
Diagram of the step-down pathway through addiction treatment: detox, residential, partial hospitalisation, intensive outpatient, then outpatient and aftercare
Nobody needs every step. The ladder exists so that support can be reduced as stability improves, not so that everyone starts at the top.
Table showing when to call 911, 988 or the SAMHSA National Helpline for overdose, immediate danger, suicidal thoughts, severe distress and treatment questions
All three are free and staffed around the clock. 988 is the Suicide & Crisis Lifeline; the SAMHSA National Helpline is 1-800-662-4357.

Common questions

Which one is stronger?

Methadone is a full agonist with no ceiling effect, so at higher doses it produces greater opioid activity. That is a difference in pharmacology, not a ranking of which treats addiction better.

Can you switch between them?

Yes, and it is done regularly when one is not working well. Switching requires medical supervision because of timing and precipitated withdrawal risk.

Does insurance cover them?

Medication for opioid use disorder is covered by most plans including Medicaid, though prior authorisation rules and which programmes are in network vary considerably.

Is this just replacing one drug with another?

This framing persists but does not match the clinical evidence: at a stable therapeutic dose these medications prevent withdrawal and craving without intoxication, and are associated with substantially reduced mortality compared with no medication.

Sources

How this page was made

Who wrote it:
the Westbrook Recovery editorial team : researchers and writers, not clinicians. No doctor has reviewed this page, and we do not claim otherwise. What that means in practice: we report what public clinical sources say and show you where to read them, rather than offering a clinical opinion of our own.
Checked against:
9 primary sources listed above: federal agency material and published clinical criteria. Where a figure varies by state, plan or facility, we say so instead of publishing a number that looks authoritative and is not.
Original analysis:
the facility proportions on this page are our own count of SAMHSA’s public directory. The full method is documented , including what we count, what we deliberately do not publish, and an error the approach caught. You can repeat the pull and check the numbers.
Last reviewed:
. This date changes when the content is actually re-checked, not automatically on every visit.
What this page is not:
a medical recommendation, a diagnosis, or a referral. Decisions about levels of care and medication belong with a clinician who knows your history. We do not operate facilities, take placement fees, or receive payment for sending anyone anywhere.

Related comparisons

  • Sober Living Home vs Halfway HouseSober living is privately paid and open-ended; a halfway house is usually assigned with a fixed time limit. Cost, rules, testing and stay length compared.
  • PHP vs IOPPHP runs 20-30 structured hours a week and IOP runs 9-19. The real question is whether home can hold the other 148 hours.
  • Detox vs RehabDetox manages withdrawal safely, rehab treats why the drug or alcohol use started, and detox alone rarely holds. What each stage does, how long, and when.

Practical guides

Check your coverage

This page is information, not medical advice. Treatment decisions belong with a qualified clinician who knows your history. If you are in crisis, call or text 988 in the US, or reach the SAMHSA National Helpline at 1-800-662-4357 — free, confidential, 24/7.